Impaired inhibitory processing: a new therapeutic target for autism and psychosis?

Kareen Heinze, Helen C. Barron, Emma K. Howes, Mani Ramaswami, Matthew R. BroomeThe British Journal of Psychiatry 2020 · DOI

Introduction: Beyond Diagnostic Silos

Traditionally, clinical psychiatry has treated autism and psychosis as distinct entities. Autism is typically diagnosed in early childhood, while psychosis often emerges in late adolescence. However, epidemiological data suggests a significant overlap: the two conditions co-occur as disorders in 8–12% of cases, and their traits overlap in up to 31% of patients.

This paper argues that current diagnostic hierarchies, such as those in the DSM-5, fail to capture the shared underlying neurobiological mechanisms. By adopting a "Research Domain Criteria" (RDoC) approach, researchers can identify biological commonalities—specifically the balance between neural excitation and inhibition (E/I balance)—that explain how diverse genetic and environmental risks manifest as shared symptoms like sensory overload and social deficits.

The GABAergic Hypothesis and E/I Balance

The central mechanism proposed is a breakdown in the brain's "brakes": the GABAergic system. Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter responsible for quenching neural signals and maintaining stability. When GABAergic function is impaired, the E/I balance shifts. This shift causes minor signal gating errors to amplify into profound cognitive changes.

Specific cellular players, such as parvalbumin-positive (PV+) interneurons, are critical for "gain control" over incoming signals. If these cells fail, the brain loses its ability to filter irrelevant information. Interestingly, the timing of biological "hits" to this system is crucial; GABA acts as an excitatory transmitter in early development before switching to inhibitory. The developmental window in which dysfunction occurs may determine whether the clinical outcome manifests as autism or psychosis.

A Unified Framework: The Bayesian Brain

To explain why a shared mechanism leads to different symptoms, the authors employ a Bayesian hierarchical generative model. This framework suggests that the brain constantly balances incoming sensory data against internal expectations (priors).

A conceptual framework linking risk factors to altered social behavior through GABAergic dysfunction and E/I imbalance.

In this model, the E/I imbalance leads to the "overweighting" of different information types:

  • Autism: Characterized by "weak priors" and an overweighting of sensory input. This results in sensory hypersensitivity and behavioral rigidity, as the brain cannot effectively update its internal models.
  • Psychosis: Characterized by overly strong top-down priors. Here, internal models override actual sensory evidence, leading to hallucinations and delusions.

Cross-Diagnostic Evidence

The paper synthesizes findings from multiple methodologies to support this hypothesis. Post-mortem analyses have revealed reductions in GABA-synthesizing enzymes (GAD65 and GAD67) in both conditions. Genetic mouse models further support this; for instance, deletion of the NRG1 receptor—a risk factor for psychosis—leads to a 30% decrease in PV+ interneurons. Similarly, mutations in CNTNAP2, linked to autism, also result in reduced interneuron counts.

In vivo neuroimaging using Proton Magnetic Resonance Spectroscopy ($^1$H-MRS) and EEG/MEG has attempted to track these changes in humans. While $^1$H-MRS results have been inconsistent—possibly because it measures total GABA rather than the active neurotransmitter pool—gamma oscillations (tracked via EEG) consistently point toward interneuron dysfunction.

Therapeutic Potential and Future Directions

Identifying a shared mechanism opens the door for cross-diagnostic treatments. Pharmacological interventions like bumetanide, which reinforces GABAergic inhibition, have shown promise in improving face processing in autism. Similarly, GABA agonists are already used to treat catatonia in both conditions.

However, significant challenges remain. Current imaging lacks the anatomical resolution to pinpoint specific brain regions driving these changes. Furthermore, there is a pressing need for "stratification markers"—biological signatures derived from TMS or ultra-high-field imaging. These markers would allow clinicians to group patients by their specific physiological dysfunction rather than outward symptoms, enabling tailored treatments that move beyond traditional diagnostic labels.

Summary updated

Abstract

In the healthy brain, homeostatic balance between excitation and inhibition maintains neural stability. Reduced inhibition may explain shared symptoms observed in autism and psychosis. Here we review evidence suggesting that altered levels of gamma-aminobutyric acid (GABA) may underlie both disorders, providing a potential cross-diagnostic therapeutic target.
BibTeX
@article{heinze2020impaired,
  author = {Kareen Heinze and Helen C. Barron and Emma K. Howes and Mani Ramaswami and Matthew R. Broome},
  title = {{Impaired inhibitory processing: a new therapeutic target for autism and psychosis?}},
  journal = {The British Journal of Psychiatry},
  year = {2020},
  doi = {10.1192/bjp.2020.163},
}
Figure